Medtronic is sponsoring the HeartWare™ HVAD™ Destination Therapy (DT) Post Approval Study (PAS) to further confirm safety and effectiveness of the HeartWare Ventricular Assist Device System (HVAD System) when used as intended, in "real-world" clinical practice. The Destination Therapy Post Approval Study (DT PAS) is conducted within Medtronic's Product Surveillance Platform.
The HeartWare Destination Therapy (DT) Post Approval Study (PAS) is a prospective, observational, multi-site study. Enrollment into the DT PAS will be comprised of newly enrolled, commercial use DT patients with the HeartWare Ventricular Assist Device System (HVAD System). Patients enrolled in DT PAS will be followed for 5 years post-implant or until study closure, patient death, patient exit from the PAS (i.e., withdrawal of consent), or patient has HVAD device removed without replacement (i.e., transplant, recovery) or device is exchanged for non-HVAD. The total estimated study duration is approximately 7 years.
Study Type
OBSERVATIONAL
Enrollment
300
The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
Long-term complication free survival
Complications include death, disabling stroke, or device malfunction or failure requiring exchange, explantation or urgent transplantation.
Time frame: Implant to 2 years
Rate of stroke
The rate of stroke on device will be analyzed using Kaplan-Meier methods.
Time frame: Implant to 2 years
Rate of late stroke
The rate of late stroke on device will be analyzed using Kaplan-Meier methods for those surviving stroke-free for 24 months post-implant.
Time frame: 2 years post-implant to 5 years
Stroke severity
Modified Rankin Scale (mRS) scores will be collected at the time associated with stroke on device and at 12 and 24 weeks post-stroke. The distribution of mRS scores for all strokes occurring in the study will be presented, separating stroke occurring prior to 24 months post-implant and those occurring greater than 24 months post-implant.
Time frame: Occurrence of stroke to 24 weeks post-stroke
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Saint Vincent Heart Clinic Arkansas
Little Rock, Arkansas, United States
University of California San Diego
San Diego, California, United States
University of California San Francisco Medical Center
San Francisco, California, United States
Stanford University Hospital
Stanford, California, United States
University of Colorado
Aurora, Colorado, United States
University of Miami
Coral Gables, Florida, United States
Mayo Clinic (Jacksonville FL)
Jacksonville, Florida, United States
AdventHealth
Orlando, Florida, United States
University of South Florida Health
Tampa, Florida, United States
Northwestern University
Chicago, Illinois, United States
...and 37 more locations